GlaxoSmithKline Pharmaceuticals Limited

GLAXO

Quarterly results

Revenue and net profit

₹ crore

Drag across a chart to read any period; every figure is listed under it. Tap the name of a metric for its year-on-year change.

  • Income
  • ₹ crore

    Sept 20261,180

    Quarter₹ croreYoY
    Sept 20241,000+4.9%
    Dec 2024946+17.6%
    Mar 2025966+6.1%
    Jun 2025805-0.8%
    Sept 2025974-2.6%
    Dec 20251,023+8.1%
    Mar 2026989+2.4%
    Jun 2026924+14.9%
    Sept 20261,180+21.2%
  • ₹ crore

    Sept 202673

    Quarter₹ crore
    Sept 202432
    Dec 202435
    Mar 202539
    Jun 202544
    Sept 202531
    Dec 202532
    Mar 202636
    Jun 202662
    Sept 202673
  • ₹ crore

    Sept 20261,253

    Quarter₹ crore
    Sept 20241,032
    Dec 2024981
    Mar 20251,006
    Jun 2025849
    Sept 20251,005
    Dec 20251,054
    Mar 20261,025
    Jun 2026986
    Sept 20261,253
  • Cost structure
  • ₹ crore

    Sept 2026170

    Quarter₹ crore
    Sept 2024151
    Dec 2024125
    Mar 2025153
    Jun 2025153
    Sept 2025138
    Dec 2025152
    Mar 2026165
    Jun 2026159
    Sept 2026170
  • ₹ crore

    Sept 2026795

    Quarter₹ crore
    Sept 2024698
    Dec 2024675
    Mar 2025651
    Jun 2025570
    Sept 2025657
    Dec 2025677
    Mar 2026656
    Jun 2026648
    Sept 2026795
  • Exceptional items and tax
  • ₹ crore

    Sept 2026458

    Quarter₹ crore
    Sept 2024339
    Dec 2024306
    Mar 2025355
    Jun 2025279
    Sept 2025351
    Dec 2025378
    Mar 2026369
    Jun 2026338
    Sept 2026458
  • ₹ crore

    Sept 2026123

    Quarter₹ crore
    Sept 202490
    Dec 202478
    Mar 202595
    Jun 202574
    Sept 202596
    Dec 2025101
    Mar 202694
    Jun 202685
    Sept 2026123
  • Profit
  • ₹ crore

    Sept 2026335

    Quarter₹ croreYoY
    Sept 2024249+15.4%
    Dec 2024229+402.5%
    Mar 2025260+34.7%
    Jun 2025205+12.7%
    Sept 2025255+2.5%
    Dec 2025277+21.3%
    Mar 2026275+5.7%
    Jun 2026253+23.8%
    Sept 2026335+31.2%
  • Per share
  • ₹ per share

    Sept 202619.76

    Quarter₹ per share
    Sept 202414.45
    Dec 202413.49
    Mar 202515.35
    Jun 202512.08
    Sept 202514.92
    Dec 202516.36
    Mar 202616.23
    Jun 202614.95
    Sept 202619.76
  • Leverage
  • Debt to equity

    times

    Mar 20260.00x

    Quartertimes
    Sept 2024—
    Dec 2024—
    Mar 20250.00x
    Jun 2025—
    Sept 2025—
    Dec 2025—
    Mar 20260.00x
    Jun 2026—
    Sept 2026—
₹ croreSept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026Sept 2026
Income
1,0009469668059741,0239899241,180
Revenue YoY+4.9%+17.6%+6.1%-0.8%-2.6%+8.1%+2.4%+14.9%+21.2%
323539443132366273
1,0329811,0068491,0051,0541,0259861,253
Cost structure
151125153153138152165159170
698675651570657677656648795
Exceptional items and tax
339306355279351378369338458
90789574961019485123
Profit
249229260205255277275253335
Net profit YoY+15.4%+402.5%+34.7%+12.7%+2.5%+21.3%+5.7%+23.8%+31.2%
Per share
14.4513.4915.3512.0814.9216.3616.2314.9519.76
Leverage
Debt to equity——0.00x———0.00x——

Latest filed period ends Sept 2026. Figures are in ₹ crore except rows named with a %, which are percentages, and EPS, which is rupees per share. An asterisk on a YoY figure means the prior period was a loss, so the percentage is computed on its absolute value. Click an underlined row name for its year-on-year change, against the same period a year earlier — blank where that period was not filed, or, on rows other than revenue and net profit, where it is not one of the 9 shown. Every blank change says which of the two it is when you rest on the dash, so a gap in the oldest columns need not be read as no growth. Rows that are already a ratio carry no change: a move from 2.00% to 2.24% is 24 basis points, not a percentage.

VValue Huddle

Indian company filings, read properly. Ownership, results and pledges.

The data

  • 2,914 companies
  • Screener built 16 Nov 2026
  • No share prices, by design

Figures may contain errors of transcription or of the filing itself. Nothing here is investment advice, a recommendation, or a share price. Companies revise their filings; where we hold a revision, the revised figure is the one shown.